Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Skorpios Trust Sells 1,937,500 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Stoke Therapeutics Stock Down 3.1 %

Shares of STOK opened at $12.86 on Wednesday. The firm has a market cap of $670.28 million, a price-to-earnings ratio of -5.34 and a beta of 0.96. The company’s fifty day moving average is $14.44 and its 200-day moving average is $13.28. Stoke Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The firm had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Redmile Group LLC lifted its holdings in Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after purchasing an additional 2,447,543 shares during the last quarter. Lynx1 Capital Management LP raised its position in shares of Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Stoke Therapeutics in the second quarter worth $19,835,000. Baker BROS. Advisors LP lifted its stake in shares of Stoke Therapeutics by 65.9% in the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after buying an additional 1,338,309 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the period.

Analyst Ratings Changes

A number of brokerages recently commented on STOK. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $21.40.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.